Effects of Bariatric Surgery in Male Obesity-Associated Hypogonadism
The prevalence of obesity has grown exponentially over the last several decades. Research has linked male obesity to changes in the gonadal axis, which can induce functional hypogonadism. Bariatric surgery provides sustained weight loss and metabolic improvement. This was a retrospective cohort study to evaluate the male gonadal axis and metabolic profiles of obese individuals during the bariatric pre- and post-operative periods while comparing them to a normal body mass index (BMI) group.
Twenty-nine obese men, who underwent bariatric surgery between 2012 and 2016 at the Federal University of Santa Catarina Hospital and a control group (CG) of 29 age-matched men with normal BMI, were analyzed. Bariatric pre- and 6-month post-operative data were compared with the CG.
The study group (G1) presented an average age, weight, and BMI of 42.8 ± 9.5 years, 155.2 ± 25.8 kg, and 50.6 ± 7.1 kg/m2, respectively. The pre-operative total testosterone (TT) G1 values were different from the CG (229.5 ± 96.4 versus 461.5 ± 170.8 ng/dL, p < 0.01). Bariatric surgery promoted a statistically significant improvement in weight, TT, and metabolic profiles in surgical patients.
Functional hypogonadism is prevalent in obese men, and we must be aware of this diagnosis. Although studies defining the best diagnostic parameters and indication of adequate hormone replacement therapy are lacking, an increase in TT levels during the first 6 months after bariatric surgery was identified in our study. Previous studies have shown that gonadal function can normalize after metabolic improvement.
KeywordsObesity Testosterone Bariatric surgery Hypogonadism
This article has no grant support.
Compliance with Ethical Standards
The study protocol was approved by the ethics committee and institutional review at Federal University of Santa Catarina and was compliant with the Helsinki Declaration. Informed consent was obtained from all participants.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–67.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009. 62 pGoogle Scholar
- 16.Hohl A, Ronsoni MF. Male hypogonadism in: endocrinology and diabetes—a problem-oriented approach, vol. 1. 1a ed. New York: Springer; 2014. p. 173–92.Google Scholar
- 27.Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–33.CrossRefPubMedGoogle Scholar
- 41.Ministério da Saúde. PORTARIA No 424, DE 19 DE MARÇO DE 2013. Redefine as diretrizes para a organização da prevenção e do tratamento do sobrepeso e obesidade como linha de cuidado prioritária da Rede de Atenção à Saúde das Pessoas com Doenças Crônicas. [Internet]. Poder Executivo, Brasília, DF.; [citado 13 de maio de 2018]. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt0424_19_03_2013.html.
- 42.Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72.Google Scholar
- 45.Organização Mundial de Saúde - OMS. Physical status: the use and interpretation of anthropometry [Internet]. Geneva: WHO; 1995. Disponível em: http://www.unu.edu/unupress/food/FNBv27n4_suppl_2_final.pdf Google Scholar